United States: Cannabis Group Weekly Alert - Week Of July 9, 2019

Last Updated: July 30 2019
Article by Kathryn Ashton, Eric P. Berlin, Ausra Deluard, David C. Quam and Joanne Caceres

In this week’s edition:

  • Congress has been spending increased time discussing cannabis reform
  • California extends provisional licenses to 2022
  • Social use laws continue to proliferate, with Massachusetts and Michigan both advancing provisions to allow for it
  • New York City’s CBD-infused food and beverage ban takes effect
  • Canopy decided to remove its founder and CEO Bruce Linton
  • Bonus: Eric Berlin pens editorial regarding cannabis legalization


The House Judiciary Crime, Terrorism and Homeland Security Subcommittee will hold a hearing on July 10 titled “Marijuana Laws in America: Racial Justice and the Need for Reform.” Based on the title and witness list, which is made up of four progressive cannabis reform advocates, it is being slated as “one of the most significant congressional developments on marijuana reform to date.”

Lawmakers are reportedly growing impatient for the Food and Drug Administration (FDA) to issue rules for CBD. Senate Majority Leader Mitch McConnell (R-KY) met with Sharpless last week, and urged the agency to speed up the timing on CBD regulation. Additionally, the House approved a provision in the appropriations bill that provides $100,000 for FDA to set a “safe level for conventional foods and dietary supplements containing cannabidiol (CBD).” There are also rumors that legislation regarding CBD is being privately circulated in Congress.

US Customs and Border Protection issued a warning for those crossing between Canada and Michigan over the Fourth of July weekend, which included a tip against the attempted entry of cannabis products into the US.


California Gov. Gavin Newsom (D) signed a bill to extend provisional licenses for cannabis businesses to 2022.

Colorado Gov. Jared Polis (D) launched an online tool to track his administrative priorities, including cannabis-related priorities. Gov. Polis hopes to increase the number of banks serving cannabis businesses, implement delivery services and triple outdoor hemp cultivation in the state.

Hawaii Gov. David Ige (D) has until July 9 to make his final decision on issuing vetoes. Among the 20 bills he has identified to potentially veto are a law creating a hemp program and a law allowing inter-island transport of medical cannabis. Although lawmakers considered convening a special session to override potential vetoes, such plans did not come to fruition due to disagreement between the House and the Senate.

Idaho Secretary of State Lawerence Denney forwarded a medical cannabis ballot measure to the state attorney general for review. This is the first step to having a measure on the ballot in 2020. The measure would decriminalize the possession of up to four ounces of cannabis for registered patients with a specified “debilitating medical condition,” such as cancer or chronic pain. 

In Illinois, the Chicago Board of Education removed cannabis and other drug use from the most serious category of infractions, removing expulsion as a possible punishment.

Kansas Gov. Laura Kelly (D) signed “Claire and Lola’s Law,” which creates an affirmative defense for those who cannot seek relief from pharmaceutical medications to possess and use CBD oil that contains less than five percent THC.

Massachusetts regulators posted draft rules for adult-use and medical cannabis and scheduled hearings to receive public comment. Per the commission, the revisions address fees; new license types, including delivery and social consumption; application, enforcement and administrative processes; operational issues, including cash handling procedures, transactions and potency limits; and energy and environmental issues, among other policy areas.

Michigan Gov. Gretchen Whitmer (D) signed a set of emergency rules for the state’s cannabis program that include provisions allowing home delivery, cannabis consumption lounges and special festival permits. The early release is intended to give Michigan’s local governments time to decide whether they want to ban adult-use cannabis businesses before the state begins accepting business license applications.

Missouri regulators released the names of individuals and businesses that have applied for licenses to cultivate, test and sell medical cannabis following a court ruling ordering them to do so.

New Jersey Gov. Phil Murphy (D) signed a bill expanding the state’s medical cannabis program. The new law aims to address several issues in the medical market by adding providers to the program, allowing patients to purchase more cannabis at once, and ending the tax charged on medical cannabis purchases by 2022. Gov. Murphy also recently stated he won’t rule out decriminalizing cannabis possession in the absence of broader legalization.

New Mexico’s cannabis decriminalization law took effect. Possessing half an ounce of cannabis is now treated with a $50 fine instead of jail time. New Mexico is the 24th state to approve cannabis decriminalization. 

In New York, Erie County’s district attorney announced that his office will no longer charge people with misdemeanors for possessing two ounces or less of cannabis and would instead issue violations. As part of his announcement, the district attorney encouraged any person previously convicted of certain minor possession crimes to file a motion to have their criminal record sealed.

North Carolina is the latest state considering a ban on smokable hemp (defined as all hemp “in a form that allows THC to be introduced into the human body by inhalation of smoke.”). This year, Indiana, Louisiana and Texas have banned smokable hemp, while Kansas banned products including hemp cigarettes and cigars. Tennessee prohibited smokable hemp sales to minors.

Oklahoma’s medical cannabis sales are exceeding projections, in part due to more than 3.5 percent of the state’s population already being registered to participate in the program.

Pennsylvania’s Department of Health issued a cease and desist order to a cultivation facility, AGRiMED, after several problems were noted during a surprise inspection. AGRiMED will be able to grow plants to cultivate its unique strains but is prohibited from removing anything from the plants outside the presence of a department inspector.

The chief of the South Carolina Law Enforcement Division spoke about his opposition to medical cannabis. He stressed that cannabis “is not medicine” and that medicine should be approved by a normal FDA process, not by a legislature.

Four Texas district attorneys announced they would not prosecute low-level possession cases without lab tests demonstrating that seized products are not legal hemp.

Utah regulators are expected to select winners of medical cannabis cultivation licenses this month.

Hemp / CBD

The FDA’s Principal Deputy Commissioner and Acting CIO Dr. Amy Abdernethy tweeted her views about CBD. She stated, “In all of this, safety is paramount. CBD is not a risk-free substance, and we need to make sure we understand its potential adverse effects as well as its potential benefits.”

A May 2019 Gallup poll asked Americans about their trust in federal agencies. The Food and Drug Administration ranked near the bottom, beating only the Veterans Administration and the Environmental Protection Agency.

Senate Majority Leader Mitch McConnell (R-KY) personally led US Agriculture Secretary Sonny Perdue on a tour of a Kentucky hemp farm and processing facility so he could get an up-close look at hemp and CBD products.

Maine regulators updated a frequently asked questions page on hemp licensing, including announcing an “Indoor Hemp Growing Trial.” While the department establishes new rules to support indoor hemp growing, 10 indoor hemp growing licenses will be issued as a trial. The 10 applications will be randomly selected from the entire pool of completed applications received by July 31, 2019.

Despite applications only being available for one week, Nebraska regulators received 176 applications for hemp licenses.

New York City’s ban on CBD-infused foods and drinks went into effect.


The UN’s 2019 World Drug Report found that cannabis was the most widely used drug around the world in 2017. In the United States, annual cannabis use rose from 9.9 percent of the adult population in 2007 to 15.3 percent a decade later. High levels of cannabis use have also been reported in Canada.

A Canadian federal court granted a medical cannabis patient the right to possess a kilogram of cannabis at a time. The patient is authorized by his doctor to consume 100 grams a day, and the 150-gram possession limit was found to impede the patient’s constitutional rights.

Provincial officials in Toronto, Ontario, report a huge decrease in the number of illicit dispensaries. The persistence of the black market has been an issue in many if not all legal adult-use and medical cannabis markets.

Trinidad and Tobago are considering legislation to decriminalize cannabis and create a regulatory framework for medical cannabis. Details of the bill are not yet public. Cabinet approval for the draft legislation is needed before it is tabled in Parliament and debated.


Canopy decided to remove its founder and CEO Bruce Linton from the position and board. Linton co-founded Canopy in 2013.

Haleigh’s Hope, Inc., announced it obtained Good Manufacturing Practices certification from the Food and Drug Administration. Haleigh’s Hope, Inc., creates and sells whole-plant hemp extracts.

Medical / Health

New research published in JAMA Pediatrics suggests legalizing adult use in some states may have slightly reduced teens' odds of using cannabis. The research reviewed responses from 1.4 million high school students from 1993 through 2017. Previous research has found no effect on teen use from medical cannabis laws, and conflicting results from adult use laws. 

A study found that cannabis sativa L. extract and cannabidiol inhibit in vitro mediators of skin inflammation and wound injury. The effect of just cannabidiol versus the full cannabis extract led researchers to conclude cannabidiol was mainly responsible for the observed effect.

A review and meta-analysis of cancer cachexia treatment found that “cannabinoid is effective in increasing appetite in cancer patients,” but that “it declines the quality of life, which may be due to the side effects of cannabinoid.” The review included three studies tracking 592 participants.

A survey of two retail stores in Colorado of 1,000 adult-use-only customers found that these customers report using cannabis for medical reasons, with 65 percent using it for pain, 74 percent using it as a sleep aid and 82 percent reducing or stopping use of over-the-counter or prescription drugs like opioids.

The New York Times examined the effects of cannabis legalization in Colorado.


In an article for Healio Gastroenterology, Dentons’ Eric Berlin argues that the medical establishment should accept that further cannabis legalization and medical cannabis use are now inevitable and work to understand better the impact on patients, how to incorporate medical cannabis into their practices and how to speak openly and honestly about the substance with patients and colleagues.

About Dentons

Dentons is the world's first polycentric global law firm. A top 20 firm on the Acritas 2015 Global Elite Brand Index, the Firm is committed to challenging the status quo in delivering consistent and uncompromising quality and value in new and inventive ways. Driven to provide clients a competitive edge, and connected to the communities where its clients want to do business, Dentons knows that understanding local cultures is crucial to successfully completing a deal, resolving a dispute or solving a business challenge. Now the world's largest law firm, Dentons' global team builds agile, tailored solutions to meet the local, national and global needs of private and public clients of any size in more than 125 locations serving 50-plus countries. www.dentons.com.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions